Product image unavailable

Bendamustine

Vendor: Marketplace supplier

Formulations: - Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL Indications: - Chronic lymphocytic leukaemia or small lymphocytic lymphoma - Follicular lymphoma Source: EML workbook import

Product metadata will be available once the catalog entry is complete.

Kes0.00

VariantSupplierQuantity

Availability

Supplier and price will be confirmed during RFQ.

View Cart

Similar Products

Ifosfamide

Formulations: - Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection Indications: - Other specified malignant neoplasms of the ovary - Germ cell tumour of testis - Ewing sarcoma of bone and articular cartilage of unspecified sites - Osteosarcoma of bone and articular cartilage of unspecified sites - Rhabdomyosarcoma primary site - Unspecified malignant neoplasms of ill-defined or unspecified sites - Burkitt lymphoma including Burkitt leukaemia - Malignant neoplasms of kidney, except renal pelvis - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive Source: EML workbook import

MOQ: 1

Kes0.00

Oxaliplatin

Formulations: - Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial Indications: - Malignant neoplasm metastasis in large intestine - Malignant neoplasms of colon Source: EML workbook import

MOQ: 1

Kes0.00

Mercaptopurine

Formulations: - Oral > Solid: 50 mg tablet Oral > Liquid: 20 mg per mL Indications: - Unspecified malignant neoplasms of ill-defined or unspecified sites - Lymphoid leukaemia, not elsewhere classified - Acute myeloid leukaemia with recurrent genetic abnormalities - Langerhans cell histiocytosis Source: EML workbook import

MOQ: 1

Kes0.00

Melphalan

Formulations: - Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg Indications: - Plasma cell myeloma Source: EML workbook import

MOQ: 1

Kes0.00

Irinotecan

Formulations: - Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial Indications: - Malignant neoplasm metastasis in large intestine - Malignant neoplasms of kidney, except renal pelvis - Rhabdomyosarcoma primary site Source: EML workbook import

MOQ: 1

Kes0.00

Gemcitabine

Formulations: - Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection Indications: - Other specified carcinomas of ovary - Other specified malignant neoplasms of bronchus or lung Source: EML workbook import

MOQ: 1

Kes0.00

Ready to amplify your rewards? Drop your email and we'll be in touch soon.